Measurement of the Beam Energy Distribution of a Medical Cyclotron with a Multi-Leaf Faraday Cup

Nesteruk, Konrad Pawel; Ramseyer, Luca; Carzaniga, Tommaso Stefano; Braccini, S.

doi:10.3390/instruments3010004

Cited by 19 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advantage of this method is the widespread availability of appropriate cyclotrons worldwide, especially in Europe [26,27] and high amounts of clinical doses of 225 Ac could be produced in a reliable way. It is important to mention that medical cyclotrons used for the production of radioisotopes (15-25 MeV) are considered to be feasible for basic and applied research [28]. The downside with this approach is that 226 Ra is not an easy isotope to work with due to the presence of the highly radiotoxic noble gas 222 Rn in its decay chain.…”

Section: Current Strategies For 225 Ac Productionmentioning

confidence: 99%

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Ahenkorah¹,

Cassells²,

Deroose³

et al. 2021

Preprint

View full text Add to dashboard Cite

Besides external high-energy photon or proton beam therapy, targeted radionuclide therapy (TRNT) is an alternative approach to deliver radiation to cancer cells. TRNT is distributed within the body by the vascular system and allows targeted irradiation of a primary tumor and all its metastases, resulting in substantially less collateral damage to normal tissues as compared to ex-ternal beam radiotherapy (EBRT). It is a systemic cancer therapy, tackling systemic spread of the disease, which is the cause of death in most cancer patients. The α-emitting radionuclide bis-muth-213 (213Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with 213Bi are discussed in this review, covering the entire chain from radionuclide production to bedside. First, the radionuclide properties and production of 225Ac and its daughter 213Bi are discussed, followed by the fundamental chemical properties of bismuth. Next, an overview of available acyclic and macrocyclic bifunctional chelators for bismuth, and general considerations for designing a 213Bi-radiopharmaceutical are provided. Finally, we will provide an overview of preclinical and clinical studies involving 213Bi-radiopharmaceuticals, as well as the future perspectives of this promising cancer treatment option.

show abstract

Section: Current Strategies For 225 Ac Productionmentioning

confidence: 99%

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Ahenkorah¹,

Cassells²,

Deroose³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The advantage of this method is the widespread availability of appropriate cyclotrons worldwide, especially in Europe [ 22 , 23 ], and high amounts of clinical doses of 225 Ac could be produced in a reliable way. It is important to mention that medical cyclotrons used to produce radioisotopes (15–25 MeV) are considered to be feasible for basic and applied research [ 24 ]. The downside with this approach is that 226 Ra is not an easy isotope to work with due to the presence of the highly radiotoxic noble gas 222 Rn in its decay chain.…”

Section: Radionuclide Properties and Production Of 225 Ac And Its Daughter 213 Bimentioning

confidence: 99%

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

et al. 2021

View full text Add to dashboard Cite

In contrast to external high energy photon or proton therapy, targeted radionuclide therapy (TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and all its metastases, resulting in less collateral damage to normal tissues. The α-emitting radionuclide bismuth-213 (213Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with 213Bi are discussed in this review, covering the entire chain from radionuclide production to bedside. First, the radionuclide properties and production of 225Ac and its daughter 213Bi are discussed, followed by the fundamental chemical properties of bismuth. Next, an overview of available acyclic and macrocyclic bifunctional chelators for bismuth and general considerations for designing a 213Bi-radiopharmaceutical are provided. Finally, we provide an overview of preclinical and clinical studies involving 213Bi-radiopharmaceuticals, as well as the future perspectives of this promising cancer treatment option.

show abstract

“…The DUT is mounted and aligned on the remote controllable 2D stage (6). leaf Faraday cup [21], measuring the beam transmission through aluminum absorbers of different thicknesses [22] and measuring the deflection angle introduced by a dipole electromagnet [23]. Additionally, the cyclotron operation settings were tuned for low output current operation, down to the pA range.…”

Section: Drum Collimatormentioning

confidence: 99%

A facility for radiation hardness studies based on a medical cyclotron

Anders,

Braccini,

Carzaniga

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

The development of instrumentation for operation in high-radiation environments represents a challenge in various research fields, particularly in particle physics experiments and space missions, and drives an ever-increasing demand for irradiation facilities dedicated to radiation hardness studies. Depending on the application, different needs arise in terms of particle type, energy and dose rate. In this article, we present a versatile installation based on a medical cyclotron located at the Bern University Hospital (Inselspital), which is used as a controlled 18-MeV proton source. This accelerator is used for daily production of medical radioisotopes, as well as for multidisciplinary research, thanks to a 6.5-meter long beam transfer line that terminates in an independent bunker, dedicated only to scientific activities. The facility offers a wide range of proton fluxes, due to an adjustable beam current from approximately 10 pA to the micro-ampere range, together with a series of steering and focusing magnets along the beamline that allow for the beam spot to be focused down to a few mm 2 . The beamline can be instrumented with a variety of beam monitoring detectors, collimators, and beam current measurement devices to precisely control the irradiation conditions. The facility also hosts a well equipped laboratory dedicated to the characterisation of samples after irradiation. An experimental validation of the irradiation setup, with proton fluxes ranging from 5 × 10 9 cm −2 s −1 to 4 × 10 11 cm −2 s −1 , is reported in this article.

show abstract

Measurement of the Beam Energy Distribution of a Medical Cyclotron with a Multi-Leaf Faraday Cup

Cited by 19 publications

References 4 publications

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

A facility for radiation hardness studies based on a medical cyclotron

Contact Info

Product

Resources

About